154 related articles for article (PubMed ID: 32058250)
1. Mitochondria-targeting zeolitic imidazole frameworks to overcome platinum-resistant ovarian cancer.
Xing Y; Jiang Z; Akakuru OU; He Y; Li A; Li J; Wu A
Colloids Surf B Biointerfaces; 2020 May; 189():110837. PubMed ID: 32058250
[TBL] [Abstract][Full Text] [Related]
2. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
Kang X; Wang Y; Chen Z; Wu Y; Chen H; Yang X; Yu C
Chem Commun (Camb); 2020 Sep; 56(76):11271-11274. PubMed ID: 32830841
[TBL] [Abstract][Full Text] [Related]
3. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
4. ATP-triggered mitochondrial cascade reactions for cancer therapy with nanoscale zeolitic imidazole framework-90.
Pan W; Cui B; Wang K; Shi M; Lu F; Li N; Tang B
Theranostics; 2021; 11(16):7869-7878. PubMed ID: 34335969
[No Abstract] [Full Text] [Related]
5. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin prodrug conjugated Fe
Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
[TBL] [Abstract][Full Text] [Related]
7. PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.
Shen L; Zhou L; Xia M; Lin N; Ma J; Dong D; Sun L
Exp Cell Res; 2021 Jan; 398(1):112369. PubMed ID: 33220258
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria Targeted Nanoscale Zeolitic Imidazole Framework-90 for ATP Imaging in Live Cells.
Deng J; Wang K; Wang M; Yu P; Mao L
J Am Chem Soc; 2017 Apr; 139(16):5877-5882. PubMed ID: 28385016
[TBL] [Abstract][Full Text] [Related]
9. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
10. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
11. Microfluidics-Assisted Surface Trifunctionalization of a Zeolitic Imidazolate Framework Nanocarrier for Targeted and Controllable Multitherapies of Tumors.
Shen J; Ma M; Zhang H; Yu H; Xue F; Hao N; Chen H
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45838-45849. PubMed ID: 32956582
[TBL] [Abstract][Full Text] [Related]
12. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
14. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
[TBL] [Abstract][Full Text] [Related]
15. Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells.
Shin SY; Jung H; Ahn S; Hwang D; Yoon H; Hyun J; Yong Y; Cho HJ; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2014 Mar; 22(6):1809-20. PubMed ID: 24565968
[TBL] [Abstract][Full Text] [Related]
16. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
17. A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin.
Guo X; Fang Z; Zhang M; Yang D; Wang S; Liu K
Molecules; 2020 Jun; 25(11):. PubMed ID: 32512936
[TBL] [Abstract][Full Text] [Related]
18. Zeolitic Imidazole Framework/Silica Nanocomposite for Targeted Cancer Therapeutics: Comparative Study of Chemo-Drug Cisplatin (CPt) and Green Platinum (GPt) Efficacy.
Alotaibi HG; Al-Abbad E; Almohazey D; Ravinayagam V; Akhtar S; Dafalla H; Jermy BR
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542131
[TBL] [Abstract][Full Text] [Related]
19. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
